CommercialDocumentationMedium impact
08.01.13l, Brentuximab Vedotin (Adcetris®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.13l updates medical necessity criteria, medical coding guidelines, and general informational content for Brentuximab Vedotin (Adcetris®), effective October 20, 2025. The billing team must review updated authorization requirements and coding standards to ensure compliant claim submission for this specialty oncology drug.
Action Required
By October 20, 2025: Billing team must obtain and review the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-13l to identify specific medical necessity criteria, billing codes, and coding guidelines for Brentuximab Vedotin (Adcetris®). Update prior authorization templates, EMR documentation requirements, and billing system rules to reflect new medical necessity standards. Train oncology staff and providers on updated documentation requirements. Ensure all Adcetris® claims submitted on or after the effective date comply with the new criteria to prevent denials.